Skip to main content
OpenTrials
Active, not recruiting

NCT Number: NCT07778901

China Dizziness and Vertigo Cohort Study (VERIDICAL STUDY)

The goal of this observational study is to characterize the clinical features, etiological distribution, and longitudinal outcomes of patients with dizziness and/or vertigo in real-world neurological and otolaryngological outpatient settings across China. The main questions it aims to answer are:

What is the etiological spectrum of dizziness and vertigo in patients presenting to neurology and otolaryngology clinics in China, and how do diagnoses evolve over time under routine clinical practice? Additionally, how do symptoms, functional impairment, and treatment responses change during follow-up?

Participants presenting with dizziness and/or vertigo who are already receiving routine clinical care at participating hospitals will be enrolled in a multicenter registry. They will undergo baseline clinical assessment and complete standardized questionnaires, and will be followed at predefined intervals for up to 12 months (with possible extended follow-up) through outpatient visits, electronic diaries, or telephone interviews to assess diagnostic stability, symptom progression, and treatment outcomes in a real-world setting.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

6 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88 Jiefang Road

Hangzhou, Zhejiang, 310000, China

About this study

This study is designed as a prospective, multicenter, real-world observational registry based on the Chinese Headache and Vertigo Registry System (CHRS), aiming to systematically characterize the etiological spectrum, diagnostic evolution, and clinical outcomes of patients presenting with dizziness and/or vertigo across neurology and otolaryngology outpatient settings in China. Participants will be consecutively or randomly enrolled from approximately 69 hospitals across more than 30 provinces, and all clinical data will be collected using standardized electronic case report forms within the CHRS platform. The registry integrates structured baseline assessments, including demographic characteristics, detailed clinical history, neurological and otological examinations, and standardized vestibular and audiological investigations, as well as validated patient-reported outcome measures. Etiological classification will be performed according to the Bárány Society International Classification of Vestibular Disorders consensus criteria, with supplementary classification based on ICD-11 when necessary. Longitudinal follow-up will be conducted at predefined time points up to 12 months, with extended follow-up allowed when clinically indicated, to evaluate diagnostic stability, symptom evolution, treatment response, and functional outcomes under routine clinical practice.

A comprehensive data management and quality assurance framework will be implemented. The CHRS registry will incorporate predefined data validation rules, including range checks, logical consistency checks, and cross-variable verification to ensure internal data integrity. Source data verification will be performed through periodic comparison of registry entries with medical records, imaging reports, and original clinical documentation at participating sites. A detailed data dictionary will be maintained, defining each variable, coding standards (including internationally recognized terminologies where applicable), and measurement scales. Standard Operating Procedures (SOPs) will govern all aspects of registry operations, including patient recruitment, informed consent, data entry, follow-up procedures, adverse event reporting, data monitoring, and protocol amendments. Site monitoring and auditing will be conducted periodically by independent reviewers to ensure protocol adherence and data accuracy.

Missing data will be managed according to predefined rules, including documentation of missingness mechanisms (e.g., unavailable, non-reported, or out-of-range values), and handled using appropriate statistical techniques such as multiple imputation or sensitivity analyses when applicable. Sample size determination is based on expected prevalence estimates and study precision requirements, with planned enrollment of approximately 6,000 participants to ensure adequate statistical power and representativeness. A detailed statistical analysis plan will be implemented, specifying descriptive analyses, comparative analyses, longitudinal modeling, and regression-based approaches to address primary and secondary objectives. All analyses will be conducted using validated statistical software, and results will be reported in accordance with relevant guidelines for observational registry studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must meet all of the following criteria:a) Age between 18 and 65 years, inclusive;b) Male or female;c) Consecutive patients presenting to dizziness/vertigo outpatient clinics in the Departments of Neurology or Otolaryngology at 69 hospitals across more than 30 provinces in China, with symptoms of spatial orientation impairment or balance disturbance, including vertigo, dizziness, vestibular-visual symptoms, and postural symptoms;d) Ability and willingness to provide written informed consent

Exclusion criteria

  • Inability to cooperate with essential diagnostic procedures, including medical history collection, physical examination, laboratory investigations, or other required evaluations, resulting in failure to establish a basic clinical diagnosis;b) Refusal or inability to provide written informed consent.

Treatment and study plan

Primary outcomes

  1. Proportion of patient number with specific etiology of vestibular diseases

    Time frame: In every research point of follow-up, and the extended follow-up period

    For this outcome measure, we will calculate the proportion for the number of patients in each confirmed etiology of vestibular disease among the enrolled patient population or total patient count during a specific follow-up time

  2. Proportion of patients with moderate-to-severe vestibular symptoms improving to mild severity

    Time frame: In each time point to follow up within 12 months from study enrolment and during the extended follow-up phase. This proportion may be calculated for the same follow-up time period when rescue medication is administered.

    Defined as the proportion of patients from whom their moderate-to-severe vestibular symptoms improve to mild severity within the specified time window after administration of appropriate first-line acute-phase therapeutic agents selected in accordance with recommendations from disease-specific treatment guidelines.

  3. Reduction in days with vestibular symptoms relative to baseline vestibular symptom days

    Time frame: Every follow-up time point of the research

    The numeric reduction in the average number of days with vestibular symptom episodes during follow-up time point after a period of preventive treatment, compared with baseline.

  4. Reduction in frequence of vestibular symptom episode relative to baseline vestibular symptom frequence

    Time frame: Every follow-up time point of the research

    The numeric reduction in the average number of frequence with vestibular symptom episodes during follow-up time point after a period of preventive treatment, compared with baseline.

  5. Number of rescue-medication administrations during preventive treatment

    Time frame: Every follow-up time point of the research

    Number of rescue medications required for recurrent vestibular symptom episodes while on preventive medication.

Secondary outcomes

  1. Number of one more subsequent rescue-medication administrations after initial acute treatment

    Time frame: Every follow-up time point of the research

    Calculation the number of subsequent rescue medication administration after initial acute treatment to evaluate the efficiency of specific treatment drug

  2. The proportion of patient number whom whose moderate to severe vestibular symptom relieved completely

    Time frame: In each specific follow-up time point

    Calculation the proportion of patient number whom whose moderate to severe vestibular symptom relieved completely among all the patient population after initial acute drug therapy

  3. Time to full functional recovery after one vestibular symptom attack

    Time frame: In each follow-up time point

    Calculation the time window for the first rescue medication until patients achieve full recovery of abilities for daily living and work, this secondary outcome is also used to evaluate the efficiency of one specific acute therapy

  4. Reduction in scale scores related to vestibular symptoms and their associated symptoms compared to baseline scale scores

    Time frame: Within the time window of a single acute vestibular symptom episode and in each follow-up time

    calculate numeric improvement in scale scores related to vestibular symptoms and their associated symptoms relative to baseline scores following acute treatment.

  5. The number of healthcare burden associated with vestibular disease-related diagnosis and treatment within 1-year follow-up

    Time frame: The research end point in 12-month follow-up time point

    Healthcare costs, transportation expenses, work-loss costs and other expenses incurred for the diagnosis and treatment of vestibular disease during the 1-year follow-up period.

  6. The number of different adverse reactions related to any each of study treatment medication

    Time frame: In each follow-up time point from study enrolment until study termination.

    Adverse reactions associated with administered therapeutic agents occurring in patients who receive pharmacological treatment following study enrolment.

  7. The number of patients who keep using the prescribed preventive treatment medication

    Time frame: From initiation of preventive treatment until discontinuation of the preventive

    We calculate the proportion of patients continuing preventive medication during follow-up, care about the retention rate of each prophylactic drug

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Other

Registry information

Official study title

Epidemiological Investigation and Cohort Study of Vestibular Disorders in China

Acronym: dizziness

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 21, 2026
Registry last updated
Aug 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.